MLYSNasdaqPharmaceutical PreparationsFiscal year ends December 31

Mineralys Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026

$20.92+0.62 (+3.05%)

Close on Oct 19, 2026

Market cap: $1.77B
P/E (TTM): –
Dividend yield: –

Mineralys Therapeutics, Inc. cash flow statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31
Depreciation & Amortization	0.06	0.04	0	–
Stock-Based Compensation	19	11	5.06	0.46
Deferred Income Taxes	0	0	0	0
Change in Accounts Payable	0.43	4.16	2.42	3.01
Operating Cash Flow	-142	-166	-81	-29
Capital Expenditures	-0.02	-0.10	0	–
Purchase of Investments	-815	-373	-348	-72
Sale & Maturity of Investments	425	489	188	50
Investing Cash Flow	-390	115	-160	-22
Financing Cash Flow	591	116	203	128
Net Change in Cash	59	65	-38	77
Free Cash Flow	-142	-166	-81	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2025: -36.9%

Financial strength

Current ratio: 34.46
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 715.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 3.22
Dividend yield: –